vs
Alpine Income Property Trust, Inc.（PINE）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Alpine Income Property Trust, Inc.的1.6倍（$30.3M vs $18.4M），Alpine Income Property Trust, Inc.净利率更高（11.9% vs -221.3%，领先233.2%），REGENXBIO Inc.同比增速更快（43.0% vs 29.6%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 21.4%）
Alpine Income Property Trust, Inc.是一家公开交易的房地产投资信托，持有并运营美国各地的单租户净租赁商业地产组合，核心资产板块包括民生零售、工业及郊区办公物业，通过稳定的经常性租金收入为股东提供持续回报。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PINE vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$18.4M
营收增速更快
RGNX
高出13.4%
29.6%
净利率更高
PINE
高出233.2%
-221.3%
两年增速更快
RGNX
近两年复合增速
21.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.4M | $30.3M |
| 净利润 | $2.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 35.4% | -190.0% |
| 净利率 | 11.9% | -221.3% |
| 营收同比 | 29.6% | 43.0% |
| 净利润同比 | 285.3% | -31.2% |
| 每股收益（稀释后） | $0.06 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PINERGNX
| Q1 26 | $18.4M | — | ||
| Q4 25 | $16.9M | $30.3M | ||
| Q3 25 | $14.6M | $29.7M | ||
| Q2 25 | $14.9M | $21.4M | ||
| Q1 25 | $14.2M | $89.0M | ||
| Q4 24 | $13.8M | $21.2M | ||
| Q3 24 | $13.5M | $24.2M | ||
| Q2 24 | $12.5M | $22.3M |
净利润PINERGNX
| Q1 26 | $2.2M | — | ||
| Q4 25 | $1.5M | $-67.1M | ||
| Q3 25 | $-1.3M | $-61.9M | ||
| Q2 25 | $-1.6M | $-70.9M | ||
| Q1 25 | $-1.2M | $6.1M | ||
| Q4 24 | $-958.0K | $-51.2M | ||
| Q3 24 | $3.1M | $-59.6M | ||
| Q2 24 | $204.0K | $-53.0M |
毛利率PINERGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率PINERGNX
| Q1 26 | 35.4% | — | ||
| Q4 25 | 35.3% | -190.0% | ||
| Q3 25 | 16.6% | -176.3% | ||
| Q2 25 | 16.8% | -296.3% | ||
| Q1 25 | 16.0% | 13.6% | ||
| Q4 24 | 14.3% | -242.1% | ||
| Q3 24 | 47.9% | -256.6% | ||
| Q2 24 | 24.0% | -251.3% |
净利率PINERGNX
| Q1 26 | 11.9% | — | ||
| Q4 25 | 8.7% | -221.3% | ||
| Q3 25 | -9.0% | -208.3% | ||
| Q2 25 | -11.0% | -331.8% | ||
| Q1 25 | -8.3% | 6.8% | ||
| Q4 24 | -6.9% | -241.3% | ||
| Q3 24 | 22.8% | -246.3% | ||
| Q2 24 | 1.6% | -237.7% |
每股收益（稀释后）PINERGNX
| Q1 26 | $0.06 | — | ||
| Q4 25 | $0.07 | $-1.30 | ||
| Q3 25 | $-0.09 | $-1.20 | ||
| Q2 25 | $-0.12 | $-1.38 | ||
| Q1 25 | $-0.08 | $0.12 | ||
| Q4 24 | $-0.06 | $-0.99 | ||
| Q3 24 | $0.21 | $-1.17 | ||
| Q2 24 | $0.01 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $312.5M | $102.7M |
| 总资产 | $745.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PINERGNX
| Q1 26 | $2.6M | — | ||
| Q4 25 | $4.6M | $230.1M | ||
| Q3 25 | $1.2M | $274.2M | ||
| Q2 25 | $5.0M | $323.3M | ||
| Q1 25 | $6.1M | $267.9M | ||
| Q4 24 | $1.6M | $234.7M | ||
| Q3 24 | $2.6M | $255.5M | ||
| Q2 24 | $3.3M | $290.4M |
总债务PINERGNX
| Q1 26 | — | — | ||
| Q4 25 | $377.7M | — | ||
| Q3 25 | $358.2M | — | ||
| Q2 25 | $352.6M | — | ||
| Q1 25 | $356.5M | — | ||
| Q4 24 | $301.5M | — | ||
| Q3 24 | $278.9M | — | ||
| Q2 24 | $268.3M | — |
股东权益PINERGNX
| Q1 26 | $312.5M | — | ||
| Q4 25 | $279.9M | $102.7M | ||
| Q3 25 | $223.5M | $161.5M | ||
| Q2 25 | $229.8M | $213.7M | ||
| Q1 25 | $240.9M | $274.2M | ||
| Q4 24 | $253.0M | $259.7M | ||
| Q3 24 | $248.2M | $301.4M | ||
| Q2 24 | $244.0M | $348.3M |
总资产PINERGNX
| Q1 26 | $745.1M | — | ||
| Q4 25 | $715.9M | $453.0M | ||
| Q3 25 | $621.4M | $525.2M | ||
| Q2 25 | $628.4M | $581.0M | ||
| Q1 25 | $647.4M | $490.9M | ||
| Q4 24 | $605.0M | $466.0M | ||
| Q3 24 | $579.0M | $519.1M | ||
| Q2 24 | $565.8M | $569.4M |
负债/权益比PINERGNX
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 1.60× | — | ||
| Q2 25 | 1.53× | — | ||
| Q1 25 | 1.48× | — | ||
| Q4 24 | 1.19× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PINERGNX
| Q1 26 | — | — | ||
| Q4 25 | $25.8M | $-52.3M | ||
| Q3 25 | $8.7M | $-56.0M | ||
| Q2 25 | $9.1M | $-49.3M | ||
| Q1 25 | $5.8M | $33.6M | ||
| Q4 24 | $23.4M | $-31.6M | ||
| Q3 24 | $6.2M | $-40.5M | ||
| Q2 24 | $8.0M | $-45.5M |
自由现金流PINERGNX
| Q1 26 | — | — | ||
| Q4 25 | $-87.8M | $-52.8M | ||
| Q3 25 | $-48.8M | $-56.5M | ||
| Q2 25 | $-3.0M | $-49.7M | ||
| Q1 25 | $-55.5M | $32.6M | ||
| Q4 24 | $-33.4M | $-32.7M | ||
| Q3 24 | $-43.0M | $-40.9M | ||
| Q2 24 | $-13.5M | $-46.0M |
自由现金流率PINERGNX
| Q1 26 | — | — | ||
| Q4 25 | -519.4% | -174.0% | ||
| Q3 25 | -334.9% | -189.9% | ||
| Q2 25 | -20.0% | -232.8% | ||
| Q1 25 | -391.0% | 36.6% | ||
| Q4 24 | -242.4% | -154.2% | ||
| Q3 24 | -319.3% | -168.9% | ||
| Q2 24 | -108.0% | -206.2% |
资本支出强度PINERGNX
| Q1 26 | — | — | ||
| Q4 25 | 671.8% | 1.7% | ||
| Q3 25 | 394.8% | 1.7% | ||
| Q2 25 | 81.2% | 1.8% | ||
| Q1 25 | 432.0% | 1.2% | ||
| Q4 24 | 412.3% | 5.1% | ||
| Q3 24 | 365.4% | 1.3% | ||
| Q2 24 | 172.3% | 2.1% |
现金转化率PINERGNX
| Q1 26 | — | — | ||
| Q4 25 | 17.48× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.02× | — | ||
| Q2 24 | 39.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PINE
| Lease Income | $12.6M | 68% |
| Other | $5.8M | 31% |
| Other Revenue | $46.0K | 0% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
